CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Peginterferon beta-1a

Last Updated: September 7, 2018
Result type: Reports
Project Number: SR0440-000
Product Line: Reimbursement Review

Generic Name: Peginterferon beta-1a

Brand Name: Plegridy

Manufacturer: Biogen Canada Inc.

Therapeutic Area: Multiple sclerosis, relapsing-remitting

Indications: Multiple Sclerosis, relapsing

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 17, 2015

Recommendation Type: List with criteria/condition